BR112015004783A2 - moléculas de ligação de il-18 - Google Patents

moléculas de ligação de il-18

Info

Publication number
BR112015004783A2
BR112015004783A2 BR112015004783A BR112015004783A BR112015004783A2 BR 112015004783 A2 BR112015004783 A2 BR 112015004783A2 BR 112015004783 A BR112015004783 A BR 112015004783A BR 112015004783 A BR112015004783 A BR 112015004783A BR 112015004783 A2 BR112015004783 A2 BR 112015004783A2
Authority
BR
Brazil
Prior art keywords
binding molecules
bind
complex
inflammatory diseases
molecules
Prior art date
Application number
BR112015004783A
Other languages
English (en)
Other versions
BR112015004783B1 (pt
Inventor
Eberth Adina
Brannetti Barbara
Diefenbach-Streiber Beate
Carsten Silvester Kunz Christian
Michelle Campbell Emma
Anselmus Van Heeke Gino
Alfred Schlaeppi Jean-Marc
Rene Rondeau Jean-Michel
Otto Bardroff Michael
Marshall Sylwia
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015004783(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015004783A2 publication Critical patent/BR112015004783A2/pt
Publication of BR112015004783B1 publication Critical patent/BR112015004783B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo patente de invenção: "moléculas de ligação de il-18". il-18 participa tanto em imunidade inata quanto adquirida. a bioatividade de il-18 é negativamente regulada por uma proteína de ligação de il-18 (il18bp), um inibidor de ocorrência natural e altamente específico. esta proteína solúvel forma um complexo com a il-18 livre impedindo sua interação com um receptor de il-18, desse modo neutralizando e inibindo sua atividade biológica. a presente invenção descreve moléculas de ligação, em particular anticorpos ou fragmentos dos mesmos, que se ligam à il-18 e não se ligam à il-18 ligada à il-18bp (complexo il-18/il-18bp). independentemente de seu papel fisiológico, a il-18 foi mostrada mediar uma variedade de doenças autoimunes e inflamatórias. as moléculas de ligação da invenção podem ser usadas como moléculas terapêuticas para o tratamento de doenças autoimunes e inflamatórias relacionadas com a il-18 ou como ferramentas diagnósticas para caracterização, detecção e/ou mensuração da il-18 não ligada à il-18bp como componente do lago de il-18 total.
BR112015004783-1A 2012-09-07 2013-09-05 Anticorpo isolado totalmente humano, humanizado ou quimérico, que se liga especificamente a il-18, mas não se liga ao complexo il-18/proteína de ligação a il18, seu método de produção e seu uso, polinucleotídeo isolado, vetor de clonagem ou expressão, microrganismos transgênicos e seu método de produção, e composição farmacêutica e seu uso BR112015004783B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261697981P 2012-09-07 2012-09-07
US61/697,981 2012-09-07
PCT/IB2013/058317 WO2014037899A2 (en) 2012-09-07 2013-09-05 Il-18 binding molecules

Publications (2)

Publication Number Publication Date
BR112015004783A2 true BR112015004783A2 (pt) 2017-11-21
BR112015004783B1 BR112015004783B1 (pt) 2023-01-31

Family

ID=49596347

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019028128-9A BR122019028128B1 (pt) 2012-09-07 2013-09-05 Anticorpo isolado que se liga especificamente a il-18, seu método de produção e seu uso, polinucleotídeo isolado, vetor de clonagem ou expressão, microrganismos transgênicos e seu método de produção, e composição farmacêutica e seu uso
BR112015004783-1A BR112015004783B1 (pt) 2012-09-07 2013-09-05 Anticorpo isolado totalmente humano, humanizado ou quimérico, que se liga especificamente a il-18, mas não se liga ao complexo il-18/proteína de ligação a il18, seu método de produção e seu uso, polinucleotídeo isolado, vetor de clonagem ou expressão, microrganismos transgênicos e seu método de produção, e composição farmacêutica e seu uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019028128-9A BR122019028128B1 (pt) 2012-09-07 2013-09-05 Anticorpo isolado que se liga especificamente a il-18, seu método de produção e seu uso, polinucleotídeo isolado, vetor de clonagem ou expressão, microrganismos transgênicos e seu método de produção, e composição farmacêutica e seu uso

Country Status (41)

Country Link
US (4) US9376489B2 (pt)
EP (2) EP2892923B1 (pt)
JP (3) JP6404817B2 (pt)
KR (2) KR102330653B1 (pt)
CN (2) CN109517065B (pt)
AP (1) AP2015008266A0 (pt)
AR (1) AR092465A1 (pt)
AU (4) AU2013311234A1 (pt)
BR (2) BR122019028128B1 (pt)
CA (1) CA2883821C (pt)
CL (1) CL2015000532A1 (pt)
CO (1) CO7400884A2 (pt)
CR (1) CR20150121A (pt)
CU (1) CU24249B1 (pt)
CY (1) CY1123071T1 (pt)
DK (1) DK2892923T3 (pt)
EA (2) EA201992614A3 (pt)
EC (1) ECSP15013209A (pt)
ES (1) ES2804704T3 (pt)
GT (1) GT201500054A (pt)
HK (1) HK1209136A1 (pt)
HR (1) HRP20200906T1 (pt)
HU (1) HUE050464T2 (pt)
IL (2) IL237161B (pt)
JO (2) JOP20200308A1 (pt)
LT (1) LT2892923T (pt)
MA (1) MA37892A1 (pt)
MX (2) MX2015002986A (pt)
MY (1) MY174691A (pt)
PE (1) PE20150649A1 (pt)
PH (1) PH12015500466A1 (pt)
PL (1) PL2892923T3 (pt)
PT (1) PT2892923T (pt)
RS (1) RS60394B1 (pt)
SG (2) SG10201706623WA (pt)
SI (1) SI2892923T1 (pt)
TN (1) TN2015000057A1 (pt)
TW (2) TWI613217B (pt)
UY (1) UY35016A (pt)
WO (1) WO2014037899A2 (pt)
ZA (1) ZA201500954B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
WO2015032932A1 (en) * 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
JP7274259B2 (ja) * 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体
WO2017076805A1 (en) * 2015-11-02 2017-05-11 Glaxosmithkline Intellectual Property Development Limited Use of an inhibitor of il18 for treatment of acute kidney injury
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
CN108218978B (zh) * 2016-12-13 2020-05-12 沈阳何氏眼产业集团有限公司 一种重组白细胞介素18及其制备方法与应用
CN110382002A (zh) 2017-03-09 2019-10-25 Mab发现股份有限公司 特异性结合人il-1r7的抗体
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
BR112020004389A2 (pt) * 2017-09-06 2020-09-08 Yale University composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo.
WO2019213686A1 (en) * 2018-05-10 2019-11-14 The Council Of The Queensland Institute Of Medical Research Therapeutic compositions and uses therefor
US20210317200A1 (en) 2018-12-03 2021-10-14 mAbProtein Co., Ltd. Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof
CN109870570A (zh) * 2018-12-29 2019-06-11 广东云天抗体生物科技有限公司 一种检测猴il-18的酶联免疫试剂盒
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
WO2022221264A1 (en) * 2021-04-12 2022-10-20 Ethos Biosciences, Inc. Methods and compositions for analysis of acute kidney injury
TW202306989A (zh) 2021-06-22 2023-02-16 瑞士商諾華公司 用於在治療化膿性汗腺炎中使用的雙特異性抗體
JPWO2023286694A1 (pt) 2021-07-13 2023-01-19
WO2023134767A1 (zh) * 2022-01-14 2023-07-20 和径医药科技（上海）有限公司 一种靶向IL-18Rβ的抗体及其应用
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
US20230357381A1 (en) * 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH03230220A (ja) 1990-02-05 1991-10-14 Seiko Epson Corp ソート処理方法
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108460T3 (es) 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP2009047705A (ja) 1996-07-31 2009-03-05 Hayashibara Biochem Lab Inc 生物学的試料の検出方法
JP2007121310A (ja) 1996-07-31 2007-05-17 Hayashibara Biochem Lab Inc 自己免疫疾患診断剤
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
NZ505880A (en) 1998-01-23 2003-06-30 Immunex Corp IL-18 receptor polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6432678B1 (en) 1999-06-21 2002-08-13 Smithkline Beecham Corporation Macaca cynomolgus IL 18
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
IL142025A0 (en) 1999-07-20 2002-03-10 Morphosys Ag Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
JP3230220B2 (ja) 1999-10-07 2001-11-19 独立行政法人 農業技術研究機構 ブタ由来インターロイキン−１８に対するモノクローナル抗体
DE60041432D1 (de) 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
PL356836A1 (en) 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
CN101062415A (zh) * 2000-02-21 2007-10-31 应用研究系统Ars股份公司 Il－18抑制剂的应用
PT1278540E (pt) 2000-05-05 2008-07-03 Inst Nat Sante Rech Med Utilização de inibidores da il-18 para o tratamento e/ou prevenção de aterosclerose
EP1297172B1 (en) 2000-06-28 2005-11-09 Glycofi, Inc. Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
TWI313299B (en) 2000-11-30 2009-08-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
ZA200305439B (en) 2001-01-29 2004-07-15 Applied Research Systems Use of IL-18 inhibitors for the treatment and/or prevention of heat disease.
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
WO2003057821A2 (en) 2001-10-26 2003-07-17 Centocor, Inc. Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
CA2478855C (en) 2002-03-22 2013-12-17 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
FR2838444B1 (fr) 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
JP4134166B2 (ja) 2003-04-30 2008-08-13 独立行政法人科学技術振興機構 ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法
PL1622939T3 (pl) 2003-05-13 2012-08-31 Merck Serono Sa Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
JP2005052021A (ja) 2003-08-07 2005-03-03 Yokohama City インターロイキン−１８変異体タンパク質
US20050075702A1 (en) 2003-10-01 2005-04-07 Medtronic, Inc. Device and method for inhibiting release of pro-inflammatory mediator
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005075648A1 (en) 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
EP1744734A2 (en) 2004-02-20 2007-01-24 Novo Nordisk A/S Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
WO2005097998A2 (en) 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
US20070003981A1 (en) 2005-06-29 2007-01-04 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
JP4728785B2 (ja) 2005-11-30 2011-07-20 独立行政法人科学技術振興機構 Ｉｌ−１８の生物活性を有する新規ポリペプチドの生産方法、および当該ポリペプチドの産生を阻害する物質のスクリーニング方法
ES2514495T3 (es) 2006-05-25 2014-10-28 Glaxo Group Limited Anticuerpos humanizados modificados anti-interleucina-18
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
CN102065892A (zh) 2008-01-30 2011-05-18 雅培制药有限公司 用于使抗体片段结晶的组合物和方法
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
US20110150871A1 (en) 2008-08-18 2011-06-23 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
WO2010040736A2 (en) 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
EP2346901A1 (en) 2008-10-20 2011-07-27 Abbott Laboratories Antibodies that bind to il-18 and methods of purifying the same
AP3995A (en) 2008-12-23 2017-01-11 Mtn Mobile Money Sa Pty Ltd Method of and system for securely processing a transaction
US20110008766A1 (en) 2009-05-01 2011-01-13 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
MX2012009167A (es) 2010-02-09 2012-08-23 Glaxo Group Ltd Tratamiento de un trastorno metabolico.
BR112013015508B1 (pt) * 2010-12-20 2022-04-05 Medimmune Limited Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos

Also Published As

Publication number Publication date
HRP20200906T1 (hr) 2020-09-04
DK2892923T3 (da) 2020-06-29
GT201500054A (es) 2015-10-15
EP3725805A1 (en) 2020-10-21
CN104640879A (zh) 2015-05-20
SG11201501559VA (en) 2015-03-30
WO2014037899A2 (en) 2014-03-13
IL237161B (en) 2019-08-29
JP2015534546A (ja) 2015-12-03
HUE050464T2 (hu) 2020-12-28
CN109517065A (zh) 2019-03-26
AU2017272201B2 (en) 2020-01-02
CU20150022A7 (es) 2015-08-27
PE20150649A1 (es) 2015-05-14
US20160376361A1 (en) 2016-12-29
TWI613217B (zh) 2018-02-01
MA37892A1 (fr) 2016-06-30
BR122019028128B1 (pt) 2023-01-31
ZA201500954B (en) 2018-11-28
SI2892923T1 (sl) 2020-07-31
AP2015008266A0 (en) 2015-02-28
PL2892923T3 (pl) 2020-09-07
EA201992614A3 (ru) 2020-05-31
EA201590523A1 (ru) 2015-06-30
US20190085068A1 (en) 2019-03-21
CN109517065B (zh) 2022-11-04
TWI655208B (zh) 2019-04-01
IL237161A0 (en) 2015-04-30
AU2016201741B2 (en) 2017-09-07
CA2883821A1 (en) 2014-03-13
US9376489B2 (en) 2016-06-28
ECSP15013209A (es) 2018-09-30
PH12015500466B1 (en) 2015-04-20
KR102330653B1 (ko) 2021-11-23
JOP20200308A1 (ar) 2017-06-16
CN104640879B (zh) 2018-12-07
JP2019037230A (ja) 2019-03-14
IL268336B (en) 2022-03-01
HK1209136A1 (en) 2016-03-24
JP2020072704A (ja) 2020-05-14
EA034610B1 (ru) 2020-02-27
PT2892923T (pt) 2020-06-23
MX2015002986A (es) 2015-10-08
AU2020201556B2 (en) 2022-01-13
AU2020201556A1 (en) 2020-03-19
KR102207672B1 (ko) 2021-01-26
TN2015000057A1 (en) 2016-06-29
UY35016A (es) 2014-04-30
WO2014037899A3 (en) 2014-06-05
TW201827463A (zh) 2018-08-01
CL2015000532A1 (es) 2015-06-05
SG10201706623WA (en) 2017-09-28
US11111293B2 (en) 2021-09-07
LT2892923T (lt) 2020-06-25
CY1123071T1 (el) 2021-10-29
US20220098296A1 (en) 2022-03-31
KR20150047138A (ko) 2015-05-04
JO3764B1 (ar) 2021-01-31
AU2016201741A1 (en) 2016-04-07
AU2013311234A1 (en) 2015-03-05
EA201992614A2 (ru) 2020-03-31
EP2892923A2 (en) 2015-07-15
ES2804704T3 (es) 2021-02-09
US20140112915A1 (en) 2014-04-24
RS60394B1 (sr) 2020-07-31
AU2017272201A1 (en) 2018-01-04
JP6404817B2 (ja) 2018-10-17
EP2892923B1 (en) 2020-03-25
KR20210011504A (ko) 2021-02-01
BR112015004783B1 (pt) 2023-01-31
TW201414747A (zh) 2014-04-16
CO7400884A2 (es) 2015-09-30
IL268336A (en) 2019-09-26
CA2883821C (en) 2023-03-07
MX2020007022A (es) 2020-09-07
AR092465A1 (es) 2015-04-22
CU24249B1 (es) 2017-02-02
US10081677B2 (en) 2018-09-25
CR20150121A (es) 2015-05-04
PH12015500466A1 (en) 2015-04-20
JP6944509B2 (ja) 2021-10-06
MY174691A (en) 2020-05-07

Similar Documents

Publication Publication Date Title
BR112015004783A2 (pt) moléculas de ligação de il-18
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112017017076A2 (pt) inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre.
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
BR112012007365A2 (pt) proteínas de ligação à il-1
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
BR112014016299A8 (pt) imunoglobulinas de domínio variável e usos das mesmas
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
BR112014029219A8 (pt) moléculas de ligação de il-6
CL2012002415A1 (es) Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)
MX366046B (es) Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos.
IN2014DN08398A (pt)
BR112014029089A2 (pt) anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2
BR112015027249A2 (pt) método de diagnóstico de câncer
WO2011137322A3 (en) Methods and compositions for treating celiac disease
WO2014006063A3 (en) Complement split product c4d for the treatment of inflammatory conditions
BR112014029302A2 (pt) método de redução de peso
NZ716687A (en) Il-18 binding molecules
TH167242A (th) โมเลกุลการยึดเกาะ il-18
TH167242B (th) โมเลกุลการยึดเกาะ il-18

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/09/2013, OBSERVADAS AS CONDICOES LEGAIS